Clinical Study on the Efficacy and Safety of Nalfurafine Hydrochloride Orally Disintegrating Tablets in Treating Pruritus in Patients Undergoing Maintenance Hemodialysis

Inclusion Criteria: * Age range of 18-80 years old (including both ends), male or female not limited. * Chronic renal failure patients who undergo stable dialysis for 3 months or more, receive regular hemodialysis 3 times a week, and are expected to have no significant changes in treatment or rapid changes in their condition during the clinical trial period. * Within one year prior to signing the informed consent form, the effectiveness of itch treatment (including topical medications such as moisturizers/moisturizers, systemic medications such as antihistamines or antiepileptic drugs, and non pharmacological treatments) was not satisfactory. * Those who are able to understand and comply with the research procedures and methods, voluntarily participate in this study, and sign a written informed consent form. * The number of days during which VAS values are measured at both wake-up and bedtime in the baseline period must be no less than 5 days, and the average value of the larger VAS values in morning and evening measurements must not be less than 50 mm. * The number of days evaluated for the severity of itching in Xie Chuandao during the baseline period must be no less than 5 days at both wake-up and bedtime. Exclusion Criteria: * Given poor compliance with dialysis treatment, researchers believe that it may affect the effectiveness and safety of clinical studies. * Patients who plan to undergo kidney transplantation or other elective surgeries during the study period. * P…